Associated Papers
Association of CYP2B6 and OPRM1 Genotypes with Methadone Dose Requirements and Serum Concentrations in a Vietnamese Cohorts.
Nguyen QG et al.
Balkan Journal of Medical Genetics : Bjmg, 2025
Combined Effect of CYP2B6 Genotype and Other Candidate Genes on a Steady-State Serum Concentration of Methadone in Opioid Maintenance Treatment.
Kringen MK et al.
Therapeutic Drug Monitoring, 2017
CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction.
Levran O et al.
Addiction Biology, 2013
Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV/AIDS treatment.
Li J et al.
Pharmacogenomics, 2012
Interindividual variability in the prevalence of OPRM1 and CYP2B6 gene variations may identify drug-susceptible populations.
Bunten H et al.
Journal of Analytical Toxicology, 2011
Contribution of cytochrome P450 and ABCB1 genetic variability on methadone pharmacokinetics, dose requirements, and response.
Fonseca F et al.
Plos One, 2011
OPRM1 and CYP2B6 gene variants as risk factors in methadone-related deaths.
Bunten H et al.
Clinical Pharmacology and Therapeutics, 2010
Select a paper to view details